In conclusion, vaccination with the DNA-based replicon vaccine plasmid PSVK-shFcG-GM/B7.1, which contained GM-CSF as adjuvants, provides insight into the important immune components of anti-tumor immunity that have a synergistic role in the immune response. Here, CSF2 is linked to neoplasm.